 Maki Nakayama
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Antigen, T-Cell | 12 | 2023 | 673 | 2.790 |
Why?
| | Autoantigens | 13 | 2025 | 427 | 2.730 |
Why?
| | Protein Precursors | 5 | 2025 | 136 | 2.180 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2025 | 3937 | 2.000 |
Why?
| | Insulin | 17 | 2025 | 2516 | 1.960 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2021 | 1146 | 1.580 |
Why?
| | Islets of Langerhans | 9 | 2023 | 847 | 1.520 |
Why?
| | T-Lymphocytes | 9 | 2023 | 1997 | 1.360 |
Why?
| | Urogenital Abnormalities | 8 | 2025 | 71 | 1.290 |
Why?
| | Urinary Tract | 9 | 2025 | 47 | 1.230 |
Why?
| | Epitopes | 5 | 2025 | 473 | 1.210 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2025 | 174 | 1.040 |
Why?
| | Peptide Fragments | 9 | 2019 | 696 | 1.030 |
Why?
| | Proinsulin | 4 | 2025 | 54 | 0.980 |
Why?
| | Insulin-Secreting Cells | 5 | 2025 | 392 | 0.900 |
Why?
| | Nephrotic Syndrome | 7 | 2021 | 43 | 0.820 |
Why?
| | Hybridomas | 5 | 2020 | 233 | 0.780 |
Why?
| | Autoimmunity | 10 | 2022 | 933 | 0.770 |
Why?
| | Vesico-Ureteral Reflux | 6 | 2025 | 38 | 0.770 |
Why?
| | Disease Susceptibility | 2 | 2021 | 344 | 0.750 |
Why?
| | CD3 Complex | 2 | 2020 | 112 | 0.740 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1133 | 0.630 |
Why?
| | Retroviridae | 1 | 2020 | 100 | 0.610 |
Why?
| | Peptides | 4 | 2023 | 998 | 0.610 |
Why?
| | Immunoassay | 1 | 2020 | 109 | 0.600 |
Why?
| | Antigens | 3 | 2021 | 348 | 0.600 |
Why?
| | Immunomodulation | 1 | 2020 | 99 | 0.580 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 138 | 0.550 |
Why?
| | Mice, Inbred NOD | 13 | 2019 | 616 | 0.530 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2018 | 71 | 0.500 |
Why?
| | Allografts | 1 | 2018 | 152 | 0.500 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2017 | 334 | 0.490 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 923 | 0.450 |
Why?
| | Podocytes | 6 | 2021 | 80 | 0.430 |
Why?
| | Animals | 33 | 2025 | 38100 | 0.420 |
Why?
| | Mutation | 9 | 2025 | 4090 | 0.420 |
Why?
| | Mice | 25 | 2025 | 18357 | 0.420 |
Why?
| | Graft Rejection | 1 | 2018 | 521 | 0.410 |
Why?
| | Pedigree | 9 | 2025 | 515 | 0.410 |
Why?
| | Genetic Predisposition to Disease | 7 | 2025 | 2399 | 0.400 |
Why?
| | Kidney | 11 | 2025 | 1498 | 0.390 |
Why?
| | Histocompatibility Antigens | 3 | 2021 | 102 | 0.380 |
Why?
| | Biomarkers | 2 | 2021 | 4302 | 0.330 |
Why?
| | Mutation, Missense | 4 | 2021 | 335 | 0.330 |
Why?
| | HLA Antigens | 2 | 2025 | 240 | 0.310 |
Why?
| | Macromolecular Substances | 1 | 2010 | 216 | 0.310 |
Why?
| | Histocompatibility Antigens Class II | 4 | 2018 | 364 | 0.300 |
Why?
| | Amino Acid Substitution | 5 | 2021 | 302 | 0.300 |
Why?
| | Antigen Presentation | 2 | 2025 | 208 | 0.290 |
Why?
| | Exome | 4 | 2025 | 229 | 0.280 |
Why?
| | Humans | 40 | 2025 | 145750 | 0.270 |
Why?
| | Alleles | 5 | 2021 | 896 | 0.250 |
Why?
| | DNA-Binding Proteins | 4 | 2025 | 1482 | 0.250 |
Why?
| | C-Peptide | 2 | 2018 | 190 | 0.240 |
Why?
| | Genetic Variation | 2 | 2021 | 976 | 0.230 |
Why?
| | Proteogenomics | 1 | 2025 | 12 | 0.230 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2018 | 48 | 0.230 |
Why?
| | Immunotherapy | 2 | 2021 | 667 | 0.220 |
Why?
| | Open Reading Frames | 1 | 2025 | 130 | 0.220 |
Why?
| | Mice, Knockout | 7 | 2023 | 3130 | 0.220 |
Why?
| | Protein Binding | 5 | 2021 | 2240 | 0.220 |
Why?
| | Autoantibodies | 3 | 2010 | 1509 | 0.210 |
Why?
| | Neoplasms | 1 | 2020 | 2913 | 0.210 |
Why?
| | Transcription Factors | 3 | 2021 | 1736 | 0.210 |
Why?
| | Transgenes | 1 | 2004 | 190 | 0.200 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2019 | 668 | 0.200 |
Why?
| | Alanine | 1 | 2004 | 169 | 0.200 |
Why?
| | Imidazolines | 1 | 2022 | 2 | 0.190 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2023 | 46 | 0.190 |
Why?
| | Forkhead Transcription Factors | 2 | 2020 | 209 | 0.180 |
Why?
| | Membrane Proteins | 2 | 2019 | 1166 | 0.180 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 36 | 0.170 |
Why?
| | Actins | 2 | 2021 | 427 | 0.170 |
Why?
| | Chemokine CCL4 | 1 | 2021 | 31 | 0.170 |
Why?
| | Nephrosis | 1 | 2021 | 6 | 0.170 |
Why?
| | Esophageal Atresia | 1 | 2021 | 32 | 0.170 |
Why?
| | Chemokine CCL3 | 1 | 2021 | 26 | 0.170 |
Why?
| | Uveitis | 1 | 2022 | 150 | 0.170 |
Why?
| | Tracheoesophageal Fistula | 1 | 2021 | 40 | 0.160 |
Why?
| | Hernia, Hiatal | 1 | 2021 | 39 | 0.160 |
Why?
| | Autoimmune Diseases | 2 | 2022 | 469 | 0.160 |
Why?
| | Hydroxybenzoates | 1 | 2020 | 11 | 0.160 |
Why?
| | Eye Abnormalities | 1 | 2020 | 17 | 0.160 |
Why?
| | Heterozygote | 4 | 2020 | 314 | 0.160 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 56 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 2 | 2011 | 100 | 0.160 |
Why?
| | Spinal Dysraphism | 1 | 2022 | 110 | 0.160 |
Why?
| | Ubiquinone | 1 | 2020 | 35 | 0.160 |
Why?
| | Homozygote | 4 | 2019 | 199 | 0.160 |
Why?
| | Beryllium | 1 | 2021 | 161 | 0.150 |
Why?
| | Microcephaly | 1 | 2021 | 104 | 0.150 |
Why?
| | Cross Reactions | 1 | 2020 | 130 | 0.150 |
Why?
| | Microfilament Proteins | 1 | 2020 | 135 | 0.150 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 174 | 0.150 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 94 | 0.150 |
Why?
| | Genotype | 1 | 2004 | 1857 | 0.150 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 38 | 0.150 |
Why?
| | Anorectal Malformations | 1 | 2021 | 113 | 0.150 |
Why?
| | Collagen Type IV | 1 | 2019 | 27 | 0.150 |
Why?
| | Genes, Reporter | 1 | 2020 | 277 | 0.150 |
Why?
| | Laminin | 1 | 2019 | 72 | 0.140 |
Why?
| | Berylliosis | 1 | 2021 | 202 | 0.140 |
Why?
| | Phenotype | 4 | 2020 | 3170 | 0.140 |
Why?
| | Drug Resistance | 1 | 2019 | 145 | 0.140 |
Why?
| | Genetic Vectors | 1 | 2020 | 335 | 0.140 |
Why?
| | rab5 GTP-Binding Proteins | 1 | 2018 | 10 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2013 | 199 | 0.140 |
Why?
| | Congenital Abnormalities | 1 | 2019 | 109 | 0.140 |
Why?
| | Fraser Syndrome | 1 | 2018 | 1 | 0.140 |
Why?
| | Protein Kinases | 1 | 2020 | 312 | 0.140 |
Why?
| | Chromogranin A | 1 | 2018 | 43 | 0.140 |
Why?
| | Immunization | 1 | 2020 | 375 | 0.140 |
Why?
| | Young Adult | 6 | 2021 | 14250 | 0.130 |
Why?
| | Heart Diseases | 1 | 2021 | 341 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 426 | 0.130 |
Why?
| | Female | 18 | 2025 | 79025 | 0.130 |
Why?
| | Tissue Donors | 1 | 2021 | 420 | 0.130 |
Why?
| | Child | 8 | 2021 | 22738 | 0.130 |
Why?
| | Recombination, Genetic | 1 | 2018 | 205 | 0.130 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2012 | 45 | 0.130 |
Why?
| | Repressor Proteins | 1 | 2020 | 429 | 0.130 |
Why?
| | Receptors, Nicotinic | 1 | 2019 | 327 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2021 | 426 | 0.120 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2601 | 0.120 |
Why?
| | Genetic Association Studies | 3 | 2025 | 371 | 0.120 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 98 | 0.120 |
Why?
| | Lung | 2 | 2021 | 4116 | 0.120 |
Why?
| | Genetic Testing | 1 | 2019 | 483 | 0.120 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 220 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 693 | 0.110 |
Why?
| | Male | 16 | 2025 | 72992 | 0.110 |
Why?
| | Adolescent | 6 | 2021 | 22569 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 532 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 638 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 838 | 0.100 |
Why?
| | DNA Mutational Analysis | 3 | 2019 | 410 | 0.100 |
Why?
| | Amino Acid Sequence | 4 | 2021 | 2131 | 0.100 |
Why?
| | Mice, Transgenic | 4 | 2009 | 2191 | 0.100 |
Why?
| | Disease Progression | 4 | 2019 | 2865 | 0.090 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 54 | 0.090 |
Why?
| | Crosses, Genetic | 2 | 2018 | 123 | 0.090 |
Why?
| | Mice, SCID | 2 | 2018 | 369 | 0.080 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 177 | 0.080 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 84 | 0.080 |
Why?
| | Xenopus | 2 | 2020 | 87 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1329 | 0.080 |
Why?
| | Glycine | 1 | 2011 | 186 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 250 | 0.080 |
Why?
| | Adoptive Transfer | 2 | 2013 | 200 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 233 | 0.070 |
Why?
| | Immunodominant Epitopes | 1 | 2009 | 27 | 0.070 |
Why?
| | Consanguinity | 2 | 2019 | 49 | 0.070 |
Why?
| | Spleen | 2 | 2013 | 508 | 0.070 |
Why?
| | Adult | 6 | 2021 | 40867 | 0.070 |
Why?
| | Models, Molecular | 3 | 2021 | 1599 | 0.070 |
Why?
| | Age of Onset | 2 | 2019 | 557 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2020 | 638 | 0.060 |
Why?
| | Signal Transduction | 1 | 2020 | 5223 | 0.060 |
Why?
| | Prognosis | 3 | 2019 | 4329 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2021 | 534 | 0.060 |
Why?
| | Poly I-C | 1 | 2005 | 58 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2018 | 4151 | 0.050 |
Why?
| | Ovum | 1 | 2004 | 30 | 0.050 |
Why?
| | Cell Movement | 2 | 2020 | 961 | 0.050 |
Why?
| | Microinjections | 1 | 2004 | 92 | 0.050 |
Why?
| | Thymus Gland | 2 | 2019 | 312 | 0.050 |
Why?
| | Child, Preschool | 4 | 2021 | 11866 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2823 | 0.050 |
Why?
| | Interferon-alpha | 1 | 2005 | 193 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 910 | 0.050 |
Why?
| | Pancreas | 2 | 2019 | 341 | 0.050 |
Why?
| | Conserved Sequence | 2 | 2018 | 244 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1764 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 3-gamma | 1 | 2022 | 1 | 0.050 |
Why?
| | Forkhead Box Protein L2 | 1 | 2022 | 3 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 3-beta | 1 | 2022 | 12 | 0.050 |
Why?
| | Oleanolic Acid | 1 | 2022 | 9 | 0.050 |
Why?
| | Retinol-Binding Proteins | 1 | 2022 | 17 | 0.050 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 5992 | 0.050 |
Why?
| | Eye Proteins | 1 | 2022 | 92 | 0.040 |
Why?
| | Interleukin-17 | 1 | 2022 | 120 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 101 | 0.040 |
Why?
| | Hemizygote | 1 | 2021 | 6 | 0.040 |
Why?
| | Genes, X-Linked | 1 | 2021 | 21 | 0.040 |
Why?
| | Infant | 3 | 2021 | 10089 | 0.040 |
Why?
| | Receptors, Interleukin | 1 | 2021 | 43 | 0.040 |
Why?
| | Pronephros | 1 | 2021 | 3 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2021 | 47 | 0.040 |
Why?
| | Zinc Fingers | 1 | 2021 | 50 | 0.040 |
Why?
| | Xenopus laevis | 1 | 2021 | 104 | 0.040 |
Why?
| | Amphibian Proteins | 1 | 2020 | 1 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 157 | 0.040 |
Why?
| | Time Factors | 1 | 2012 | 7133 | 0.040 |
Why?
| | HLA-DP beta-Chains | 1 | 2021 | 88 | 0.040 |
Why?
| | Pseudopodia | 1 | 2020 | 27 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2021 | 119 | 0.040 |
Why?
| | Morpholinos | 1 | 2020 | 30 | 0.040 |
Why?
| | Protein Stability | 1 | 2021 | 176 | 0.040 |
Why?
| | Enzyme Stability | 1 | 2020 | 73 | 0.040 |
Why?
| | Kidney Glomerulus | 1 | 2020 | 125 | 0.040 |
Why?
| | Cytoplasm | 1 | 2020 | 254 | 0.040 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2020 | 41 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1247 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2021 | 334 | 0.040 |
Why?
| | Animals, Genetically Modified | 1 | 2020 | 247 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5428 | 0.040 |
Why?
| | Chronic Disease | 2 | 2021 | 1810 | 0.040 |
Why?
| | Glomerular Basement Membrane | 1 | 2019 | 8 | 0.040 |
Why?
| | Methyltransferases | 1 | 2020 | 75 | 0.040 |
Why?
| | Web Browser | 1 | 2019 | 12 | 0.040 |
Why?
| | Larva | 1 | 2020 | 240 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2019 | 24 | 0.040 |
Why?
| | Ireland | 1 | 2019 | 32 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2019 | 156 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 550 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2019 | 119 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 117 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2018 | 6 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2018 | 58 | 0.030 |
Why?
| | Lysosomes | 1 | 2019 | 131 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2022 | 779 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2019 | 238 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 489 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 6464 | 0.030 |
Why?
| | Urogenital System | 1 | 2018 | 16 | 0.030 |
Why?
| | Genetic Loci | 1 | 2019 | 267 | 0.030 |
Why?
| | Clone Cells | 1 | 2018 | 263 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2020 | 263 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 5 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 6032 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2020 | 741 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 388 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 337 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 523 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 311 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2018 | 387 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 110 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 156 | 0.030 |
Why?
| | Exons | 1 | 2018 | 364 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2019 | 385 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2018 | 221 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 574 | 0.030 |
Why?
| | Drosophila melanogaster | 1 | 2018 | 239 | 0.030 |
Why?
| | Models, Animal | 1 | 2018 | 393 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1261 | 0.030 |
Why?
| | Family | 1 | 2020 | 684 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2019 | 494 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 896 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 835 | 0.030 |
Why?
| | Blood Glucose | 1 | 2005 | 2344 | 0.030 |
Why?
| | Cytokines | 1 | 2022 | 2069 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 461 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 669 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1036 | 0.030 |
Why?
| | Genomics | 1 | 2019 | 831 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 2000 | 0.020 |
Why?
| | Mitochondria | 1 | 2020 | 992 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2181 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3634 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2933 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2022 | 4569 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3551 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2013 | 509 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 111 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2011 | 126 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 563 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1361 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 849 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2009 | 61 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3752 | 0.020 |
Why?
| | Aged | 2 | 2019 | 26212 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1165 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2883 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 175 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8346 | 0.010 |
Why?
| | Middle Aged | 2 | 2019 | 36297 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1478 | 0.010 |
Why?
| | Aging | 1 | 2005 | 1973 | 0.010 |
Why?
|
|
Nakayama's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|